• The patient voluntarily joins the study and signs an informed consent;

• Age ≥ 18 years old, ≤ 70 years old, both men and women;

• Clinical or pathologically confirmed BCLC C-stage hepatocellular carcinoma, no further first-line treatment;

• At least one intrahepatic evaluable tumor existed, intrahepatic tumor is the primary tumor burden;

• Child-Pugh score small or equal to 7 points (Child-Pugh A-B);

• The liver tumor burden does not exceed 50% of the total liver volume;

• Patient can swallow tablet normally;

• ECOG score: 0 to 1 (according to the ECOG score classification);

• The expected survival is longer than 12 weeks;

⁃ The laboratory parameters meets the following requirements (no blood components and cell growth factors are allowed within 14 days before the first dose):

∙ Absolute neutrophil count ≥ 3.0 × 109 / L;

‣ Platelets ≥ 80 × 109 / L;

‣ Hemoglobin ≥ 90 g / L;

‣ serum albumin ≥ 28 g / L;

‣ Thyroid stimulating hormone (TSH) ≤ 1 × ULN (if abnormalities should be considered at the same time FT3, FT4 levels, patients with FT3 and FT4 levels in normal range can also be enrolled);

‣ bilirubin ≤ 1.5 × ULN (within 7 days prior to the first dose);

‣ ALT ≤ 3 x ULN and AST ≤ 3 x ULN (within 7 days prior to the first dose);

‣ AKP ≤ 2.5 × ULN; serum creatinine ≤ 1.5 × ULN;

⁃ For female that non-surgical sterilization or in childbearing age need to use a medically approved contraceptive (such as an intrauterine device, contraceptive or condom) during the study period and within 3 months after the end of the study treatment period; For female that non-surgical sterilization or in childbearing age must have a negative serum or urine HCG test within 72 hours prior to study enrollment; and must be non-lactating; for male patients whose partner in a childbearing age, effective methods of contraception should be given during the trial and at the end of Camrelizumab injection.